KPV: A Preclinical Signal, Not a Human Treatment Result

KPV is a tripeptide—a three-amino-acid sequence made of lysine, proline, and valine. It has been described as a fragment associated with alpha-melanocyte-stimulating hormone biology. ^{[3, 8]}

KPV is a common name rather than an established United States Adopted Name. FDA reported multiple salts and derivatives sold under the same common name, creating ambiguity about which substance a label or paper actually describes. ^[3]

KPV free base and KPV acetate are different active pharmaceutical ingredients with distinct chemical structures and potentially different physical, pharmacokinetic, safety, or efficacy properties. They are not automatically interchangeable. ^{[3, 2]}

FDA considered both forms not well characterized for the compounding review because of inconsistent naming and insufficient substance-specific information about identity, purity, impurities, aggregation, microbiological controls, and proposed formulation performance. ^[3]

KPV is studied because laboratory experiments suggest that it may influence inflammatory signaling. The most-cited intestinal work examined transport through PepT1 and downstream inflammatory markers in experimental systems. ^[8]

FDA found KPV promoted for broad claims involving inflammatory conditions, wound healing, skin health, nerve damage, and stroke. These promoted uses extend well beyond what the evidence establishes. ^[3]

Terms such as “anti-inflammatory” can refer to a molecular change in a dish, a tissue marker in a mouse, a symptom in a person, or a clinically meaningful disease outcome. Those are different claims and should not be collapsed into one treatment promise. ^{[8, 3]}

FDA found no clinical studies or human exposure data for KPV free base or KPV acetate by any route. It also found no human case reports and no human pharmacokinetic or pharmacodynamic studies. ^[3]

For the nominated uses of wound healing and inflammatory conditions, the nominator supplied no clinical evidence and FDA identified no human-use information. Effectiveness therefore cannot be evaluated from the available record. ^[3]

Experiments using human intestinal cell lines are still laboratory studies. The cells are human-derived, but no patient received KPV and no symptom, function, healing, hospitalization, or disease outcome was measured. ^[8]

With no administered-human evidence identified, the defensible conclusion is that KPV's benefits and risks in people are unknown. “No adverse events found” would be misleading when the underlying issue is that human exposure has not been adequately studied. ^[3]

A 2008 study reported KPV uptake through the PepT1 transporter in human intestinal cell lines and changes in experimental inflammatory signaling. This supports a mechanistic hypothesis under the study conditions, not clinical efficacy. ^[8]

The same paper reported changes in weight loss, tissue enzyme activity, and inflammatory markers in mouse colitis models. Mouse colitis models can help test biological ideas, but they do not reproduce the full complexity, treatment context, or patient-important outcomes of human inflammatory bowel disease. ^[8]

FDA noted that some cited laboratory work involved tissue or cadaver-skin models, while the nomination proposed topical products. Ex vivo penetration or cellular activity does not demonstrate that a finished topical product heals a human wound or safely treats a skin disease. ^[3]

A translational program would need a clearly identified substance and formulation, exposure data, dose-ranging and toxicity work, and controlled human studies with disease-specific outcomes. None of those steps can be replaced by a pathway diagram. ^{[3, 7]}

Because FDA identified neither clinical studies nor human exposure data, it could not characterize the frequency, severity, timing, reversibility, or risk factors for adverse effects. Missing surveillance is not reassuring safety evidence. ^[3]

Peptide aggregation can alter bioavailability and pharmacology and can contribute to immunogenicity. FDA identified no human data assessing aggregation or immune responses for KPV-related substances, so it found insufficient information to conclude that those risks are absent. ^{[3, 6]}

Synthetic-peptide production can generate truncated sequences, related peptides, residual reagents, solvents, and aggregates. A headline purity percentage alone may not identify or control every relevant impurity. ^{[3, 6]}

Safety also depends on the finished product and route. A cream, nasal preparation, oral product, and injectable product pose different formulation, microbiological, exposure, and administration questions even when marketed with the same three-letter name. ^{[3, 7]}

The original KPV nomination was withdrawn. FDA nevertheless evaluated KPV free base and KPV acetate on its own initiative because the submission was ambiguous about the substance and FDA identified significant safety concerns. ^[3]

The July 2026 review addressed possible 503A Bulks List placement in the context of nominated uses for wound healing and inflammatory conditions. It did not evaluate a marketing application for an FDA-approved drug. ^{[3, 2]}

FDA staff concluded that poor characterization, unknown historical compounding use, and the absence of human effectiveness and safety information weighed against adding either KPV form to the 503A Bulks List. ^[3]

The advisory committee's role is to advise FDA, and its recommendations are not binding. The proceeding is not FDA approval, while a recommendation against list placement is not equivalent to saying KPV is banned in every research or legal context. ^{[5, 1]}

FDA's current compounding-risk page includes KPV and highlights the absence of human exposure information plus potential immunogenicity and impurity concerns. It should be read as a focused regulatory risk assessment, not a complete clinical safety profile. ^[4]

Does a claim come from human outcomes, human exposure data, a mouse model, human intestinal cell lines, or marketing—and is that evidence level named before the claim is repeated? ^{[3, 8]}

Is the material KPV free base, KPV acetate, or another derivative, and what substance-specific testing establishes identity and purity rather than relying on the common name? ^[3]

How are the lack of human pharmacology, clinical outcomes, adverse-event data, interaction data, and immune-risk information being communicated—and what evidence would be needed to reduce those uncertainties? ^{[3, 7]}